Log in

Christopher Day Sells 1,267 Shares of Ambarella Inc (NASDAQ:AMBA) Stock

Posted on Tuesday, June 30th, 2020 by MarketBeat

Ambarella Inc (NASDAQ:AMBA) VP Christopher Day sold 1,267 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $45.92, for a total value of $58,180.64. Following the transaction, the vice president now owns 8,632 shares of the company's stock, valued at $396,381.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Shares of NASDAQ:AMBA traded up $1.36 during trading on Tuesday, hitting $45.80. 405,570 shares of the company were exchanged, compared to its average volume of 590,497. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -34.72 and a beta of 1.24. Ambarella Inc has a fifty-two week low of $36.02 and a fifty-two week high of $73.59. The firm has a fifty day moving average price of $52.98 and a two-hundred day moving average price of $55.04. The company has a current ratio of 8.91, a quick ratio of 8.48 and a debt-to-equity ratio of 0.02.

Ambarella (NASDAQ:AMBA) last posted its earnings results on Tuesday, June 2nd. The semiconductor company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.05. The business had revenue of $54.60 million for the quarter, compared to analyst estimates of $54.32 million. Ambarella had a negative return on equity of 9.00% and a negative net margin of 18.18%. The firm's revenue was up 15.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.01 EPS. As a group, research analysts predict that Ambarella Inc will post -1.52 EPS for the current year.

Several hedge funds have recently made changes to their positions in AMBA. Nuveen Asset Management LLC increased its holdings in Ambarella by 3.2% in the 4th quarter. Nuveen Asset Management LLC now owns 129,252 shares of the semiconductor company's stock worth $7,827,000 after purchasing an additional 3,971 shares in the last quarter. Aigen Investment Management LP acquired a new stake in Ambarella during the first quarter worth approximately $257,000. BNP Paribas Arbitrage SA grew its stake in Ambarella by 33.9% during the first quarter. BNP Paribas Arbitrage SA now owns 30,981 shares of the semiconductor company's stock worth $1,504,000 after purchasing an additional 7,852 shares during the period. JPMorgan Chase & Co. boosted its holdings in Ambarella by 90.6% in the first quarter. JPMorgan Chase & Co. now owns 121,651 shares of the semiconductor company's stock worth $5,907,000 after acquiring an additional 57,814 shares in the last quarter. Finally, Amalgamated Bank boosted its holdings in Ambarella by 9.5% in the fourth quarter. Amalgamated Bank now owns 5,347 shares of the semiconductor company's stock worth $324,000 after acquiring an additional 466 shares in the last quarter. Institutional investors and hedge funds own 75.11% of the company's stock.

AMBA has been the subject of a number of research reports. TheStreet lowered Ambarella from a "c-" rating to a "d+" rating in a research note on Friday, March 20th. Bank of America raised their target price on Ambarella from $44.00 to $50.00 and gave the stock an "underperform" rating in a report on Wednesday, June 3rd. Imperial Capital began coverage on Ambarella in a report on Tuesday, June 23rd. They set an "outperform" rating and a $58.00 target price on the stock. Roth Capital reduced their target price on Ambarella from $65.00 to $50.00 and set a "neutral" rating on the stock in a report on Friday. Finally, Robert W. Baird began coverage on Ambarella in a report on Thursday, May 28th. They set a "neutral" rating and a $60.00 price objective on the stock. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the company's stock. Ambarella has an average rating of "Hold" and an average price target of $59.77.

About Ambarella

Ambarella, Inc develops semiconductor processing solutions for video that enable high-definition (HD), video capture, analysis, sharing, and display worldwide. The company's system-on-a-chip designs integrated HD video processing, image processing, computer vision functionality, audio processing, and system functions onto a single chip for delivering video and image quality, differentiated functionality, and low power consumption.

Featured Story: Pattern Day Trader - What is the PDT Rule?

Insider Buying and Selling by Quarter for Ambarella (NASDAQ:AMBA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

8 Pharmaceutical Companies Working on a Coronavirus Cure

We are living through interesting times. Not an hour goes by when Americans don’t receive some reminder of the impact the coronavirus has on our lives. The race is on for an effective, FDA-approved treatment for the virus. Despite, vaccines being available for human trial in record time, we are many months away from having a viable vaccine.

However, we may be somewhat closer in finding some antiviral treatments. And if you’ve watched the market closely this week, any news on that front tends to move the market in a positive direction.

That brings up another truth of investing. There are some stocks that thrive from other stocks misery. And that’s why we’ve put together this special report. If you’re an investor who is looking to jump into this bear market, the pharmaceutical sector is a logical choice.

A combination of big-name drug companies as well as smaller startup companies are working around the clock to develop vaccines or treatments that will target the infection caused by the novel coronavirus.

View the "8 Pharmaceutical Companies Working on a Coronavirus Cure".

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.